» Articles » PMID: 10383399

Differential Pharmacological Properties and Signal Transduction of the Sphingosine 1-phosphate Receptors EDG-1, EDG-3, and EDG-5

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1999 Jun 26
PMID 10383399
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Sphingosine 1-phosphate (SPP) is a potent lipid mediator released upon cellular activation. In this report, pharmacological properties of the three G-protein-coupled receptors (GPCRs) for SPP, EDG-1, -3, and -5 are characterized using a Xenopus oocyte expression system, which lacks endogenous SPP receptors. Microinjection of the EDG-3 and EDG-5 but not EDG-1 mRNA conferred SPP-responsive intracellular calcium transients; however, the EDG-5 response was quantitatively much less. Co-expression of EDG-1 receptor with the chimeric Galphaqi protein conferred SPP responsiveness. Galphaqi or Galphaq co-injection also potentiated the EDG-5 and EDG-3 mediated responses to SPP. These data suggest that SPP receptors couple differentially to the Gq and Gi pathway. All three GPCRs were also activated by sphingosylphosphorylcholine, albeit at higher concentrations. None of the other related sphingolipids tested stimulated or blocked SPP-induced calcium responses. However, suramin, a polycyclic anionic compound, selectively antagonized SPP-activated calcium transients in EDG-3 expressing oocytes with an IC50 of 22 microM, suggesting that it is an antagonist selective for the EDG-3 GPCR isotype. We conclude that the three SPP receptors signal differentially by coupling to different G-proteins. Furthermore, because only EDG-3 was antagonized by suramin, variations in receptor structure may determine differences in antagonist selectivity. This property may be exploited to synthesize receptor subtype-specific antagonists.

Citing Articles

Sphingosine-1-Phosphate Metabolic Pathway in Cancer: Implications for Therapeutic Targets.

Rufail M, Bassi R, Giussani P Int J Mol Sci. 2025; 26(3).

PMID: 39940821 PMC: 11817292. DOI: 10.3390/ijms26031056.


Targeting sphingosine 1-phosphate and sphingosine kinases in pancreatic cancer: mechanisms and therapeutic potential.

Limbu K, Chhetri R, Kim S, Shrestha J, Oh Y, Baek D Cancer Cell Int. 2024; 24(1):353.

PMID: 39462385 PMC: 11514880. DOI: 10.1186/s12935-024-03535-7.


Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases.

Wang Y, Xu H, Zhou X, Chen W, Zhou H Med Rev (2021). 2024; 4(4):262-283.

PMID: 39135605 PMC: 11317083. DOI: 10.1515/mr-2024-0020.


To Be or Not to Be: The Divergent Action and Metabolism of Sphingosine-1 Phosphate in Pancreatic Beta-Cells in Response to Cytokines and Fatty Acids.

Gurgul-Convey E Int J Mol Sci. 2022; 23(3).

PMID: 35163559 PMC: 8835924. DOI: 10.3390/ijms23031638.


S1P Signaling Pathways in Pathogenesis of Type 2 Diabetes.

He Q, Bo J, Shen R, Li Y, Zhang Y, Zhang J J Diabetes Res. 2021; 2021:1341750.

PMID: 34751249 PMC: 8571914. DOI: 10.1155/2021/1341750.